Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Development of a 3D-printable bioactive polycaprolactone-collagen peptides filament for biomedical applications

Cantella S., Badini S., Bollati C., Madar Saheb MA., Viganò R., Lammi C.

Laboratory Study on Face & Skin, published in Sci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Sci Rep (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41444724
PMCID
PMC12738878
DOI
10.1038/s41598-025-28030-5

Abstract (original English)

This study presents a scalable, nontoxic method for fabricating a 3D printable polycaprolactone (PCL)-collagen peptides composite filament via solvent-assisted blending and a customized desktop filament extrusion system. Virgin and recycled PCL feedstocks were used to study the matrix characteristics. Scanning electron microscopy, X-ray diffraction, differential scanning calorimetry, thermogravimetric analysis, and intrinsic fluorescence spectroscopy confirmed that the composite maintains PCL's inherent crystalline and thermal properties. It also exhibits intrinsic bioactive capabilities provided by the collagen peptides. Filaments with diameters suitable for the Fused Filament Fabrication 3D printing were obtained. Tests demonstrated that the recycled matrix and the lab-scale process reduce the tensile modulus of the material. At the same time, collagen peptides enhanced tensile stiffness by creating intermolecular hydrogen bonding with the PCL. The biocompatibility of the composite has also been confirmed, while degradability studies have shown the tunability of the PCL degradation rate. Additionally, examples of 3D-printed scaffolds based on Triply Periodic Minimal Surfaces have been successfully fabricated using the PCL-collagen peptide filament. Therefore, this study demonstrates that integrating collagen peptides into a PCL matrix represents a viable, nontoxic, affordable

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansCollagenPolyestersPeptidesBiocompatible MaterialsX-Ray DiffractionTissue EngineeringMaterials TestingTensile StrengthTissue Scaffolds

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research